- Home
- OBIO vs PRQR Comparison
OBIO vs PRQR Comparison
Compare OBIO & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OBIO
- PRQR
- Stock Information
- Founded
- OBIO 2017
- PRQR 2012
- Country
- OBIO United States
- PRQR Netherlands
- Employees
- OBIO N/A
- PRQR N/A
- Industry
- OBIO Medicinal Chemicals and Botanical Products
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- OBIO Health Care
- PRQR Health Care
- Exchange
- OBIO Nasdaq
- PRQR Nasdaq
- Market Cap
- OBIO 151.3M
- PRQR 163.3M
- IPO Year
- OBIO N/A
- PRQR 2014
- Fundamental
- Price
- OBIO $2.89
- PRQR $1.70
- Analyst Decision
- OBIO Strong Buy
- PRQR Strong Buy
- Analyst Count
- OBIO 5
- PRQR 7
- Target Price
- OBIO $14.20
- PRQR $9.00
- AVG Volume (30 Days)
- OBIO 193.1K
- PRQR 470.6K
- Earning Date
- OBIO 05-12-2025
- PRQR 05-08-2025
- Dividend Yield
- OBIO N/A
- PRQR N/A
- EPS Growth
- OBIO N/A
- PRQR N/A
- EPS
- OBIO N/A
- PRQR N/A
- Revenue
- OBIO $2,886,000.00
- PRQR $21,212,711.00
- Revenue This Year
- OBIO $21.38
- PRQR $2.87
- Revenue Next Year
- OBIO $31.89
- PRQR N/A
- P/E Ratio
- OBIO N/A
- PRQR N/A
- Revenue Growth
- OBIO 30.23
- PRQR 85.91
- 52 Week Low
- OBIO $2.37
- PRQR $1.07
- 52 Week High
- OBIO $8.87
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- OBIO 48.11
- PRQR 54.59
- Support Level
- OBIO $2.76
- PRQR $1.65
- Resistance Level
- OBIO $3.02
- PRQR $1.83
- Average True Range (ATR)
- OBIO 0.18
- PRQR 0.10
- MACD
- OBIO 0.03
- PRQR -0.00
- Stochastic Oscillator
- OBIO 52.06
- PRQR 60.42
About OBIO Orchestra BioMed Holdings Inc.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the global commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics.